BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 37715926)

  • 21. Clinical observations on associations between the UGT1A1 genotype and severe toxicity of irinotecan.
    Lu YY; Huang XE; Wu XY; Cao J; Liu J; Wang L; Xiang J
    Asian Pac J Cancer Prev; 2014; 15(7):3335-41. PubMed ID: 24815493
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of UGT1A1*6, UGT1A1*28, and ABCB1-3435C>T polymorphisms on irinotecan induced toxicity in Chinese cancer patients.
    Yan L; Wang XF; Wei LM; Nie YL; Liu JY; Zhang LR
    Int J Clin Pharmacol Ther; 2016 Mar; 54(3):193-9. PubMed ID: 26857783
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of UGT1A1*6, UGT1A1*28, or ABCC2 c.3972C>T genetic polymorphisms with irinotecan-induced toxicity in Asian cancer patients: Meta-analysis.
    Atasilp C; Biswas M; Jinda P; Nuntharadthanaphong N; Rachanakul J; Hongkaew Y; Vanwong N; Saokaew S; Sukasem C
    Clin Transl Sci; 2022 Jul; 15(7):1613-1633. PubMed ID: 35506159
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: a homozygote for the SLCO1B1*15 allele.
    Takane H; Miyata M; Burioka N; Kurai J; Fukuoka Y; Suyama H; Shigeoka Y; Otsubo K; Ieiri I; Shimizu E
    Ther Drug Monit; 2007 Oct; 29(5):666-8. PubMed ID: 17898662
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer.
    Zhou Q; Sparreboom A; Tan EH; Cheung YB; Lee A; Poon D; Lee EJ; Chowbay B
    Br J Clin Pharmacol; 2005 Apr; 59(4):415-24. PubMed ID: 15801936
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive Value of
    Aoullay Z; Smith A; Slaoui M; El Bouchikhi I; Ghazal H; Al Idrissi N; Meddah B; Lynch KL; Cherrah Y; Wu AHB
    Genet Test Mol Biomarkers; 2023 May; 27(5):133-141. PubMed ID: 37257181
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients.
    Shulman K; Cohen I; Barnett-Griness O; Kuten A; Gruber SB; Lejbkowicz F; Rennert G
    Cancer; 2011 Jul; 117(14):3156-62. PubMed ID: 21287524
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prolonged neutropenia after irinotecan-based chemotherapy in a child with polymorphisms of UGT1A1 and SLCO1B1.
    Sakaguchi S; Garcia-Bournissen F; Kim R; Schwarz UI; Nathan PC; Ito S
    Arch Dis Child; 2009 Dec; 94(12):981-2. PubMed ID: 19608554
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of drug metabolizing enzymes and transporters in Thai colorectal cancer patients treated with irinotecan-based chemotherapy.
    Atasilp C; Chansriwong P; Sirachainan E; Reungwetwattana T; Sirilerttrakul S; Chamnanphon M; Puangpetch A; Sukasem C
    Sci Rep; 2020 Aug; 10(1):13486. PubMed ID: 32778670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms.
    Satoh T; Ura T; Yamada Y; Yamazaki K; Tsujinaka T; Munakata M; Nishina T; Okamura S; Esaki T; Sasaki Y; Koizumi W; Kakeji Y; Ishizuka N; Hyodo I; Sakata Y
    Cancer Sci; 2011 Oct; 102(10):1868-73. PubMed ID: 21740478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy.
    Takane H; Kawamoto K; Sasaki T; Moriki K; Moriki K; Kitano H; Higuchi S; Otsubo K; Ieiri I
    Cancer Chemother Pharmacol; 2009 May; 63(6):1165-9. PubMed ID: 18998132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pre-therapeutic UGT1A1 genotyping to reduce the risk of irinotecan-induced severe toxicity: Ready for prime time.
    Hulshof EC; Deenen MJ; Guchelaar HJ; Gelderblom H
    Eur J Cancer; 2020 Dec; 141():9-20. PubMed ID: 33125947
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan.
    Ando Y; Ueoka H; Sugiyama T; Ichiki M; Shimokata K; Hasegawa Y
    Ther Drug Monit; 2002 Feb; 24(1):111-6. PubMed ID: 11805731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype.
    Páez D; Tobeña M; Fernández-Plana J; Sebio A; Virgili AC; Cirera L; Barnadas A; Riera P; Sullivan I; Salazar J
    Br J Cancer; 2019 Jan; 120(2):190-195. PubMed ID: 30585257
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study.
    Di Martino MT; Arbitrio M; Leone E; Guzzi PH; Rotundo MS; Ciliberto D; Tomaino V; Fabiani F; Talarico D; Sperlongano P; Doldo P; Cannataro M; Caraglia M; Tassone P; Tagliaferri P
    Cancer Biol Ther; 2011 Nov; 12(9):780-7. PubMed ID: 21892003
    [TBL] [Abstract][Full Text] [Related]  

  • 36. UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians.
    Cheng L; Li M; Hu J; Ren W; Xie L; Sun ZP; Liu BR; Xu GX; Dong XL; Qian XP
    Cancer Chemother Pharmacol; 2014 Mar; 73(3):551-60. PubMed ID: 24448639
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients.
    Jada SR; Lim R; Wong CI; Shu X; Lee SC; Zhou Q; Goh BC; Chowbay B
    Cancer Sci; 2007 Sep; 98(9):1461-7. PubMed ID: 17627617
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question.
    Deeken JF; Slack R; Marshall JL
    Cancer; 2008 Oct; 113(7):1502-10. PubMed ID: 18720361
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The UGT1A1*28 genotype and the toxicity of low-dose irinotecan in patients with advanced lung cancer.
    Sugiyama T; Hirose T; Kusumoto S; Shirai T; Yamaoka T; Okuda K; Ohnishi T; Ohmori T; Adachi M
    Oncol Res; 2010; 18(7):337-42. PubMed ID: 20377135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. UGT1A1 Gene Polymorphism Predicts Irinotecan-Induced Severe Neutropenia and Diarrhea in Chinese Cancer Patients.
    Peng H; Duan Z; Pan D; Wen J; Wei X
    Clin Lab; 2017 Sep; 63(9):1339-1346. PubMed ID: 28879724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.